Olr1642 inhibitors represent a chemical class defined by their ability to selectively inhibit the function of the Olr1642 receptor, a member of the olfactory receptor family. Olfactory receptors, primarily known for their role in detecting odor molecules, are G-protein-coupled receptors (GPCRs) widely expressed in the olfactory epithelium. The Olr1642 receptor, like other olfactory receptors, has a highly conserved seven-transmembrane domain structure typical of GPCRs, which allows it to interact with specific ligands. The inhibitors of Olr1642 are typically small organic molecules designed or discovered to bind to this receptor with high specificity, effectively blocking the receptor's ability to engage in its normal ligand-binding processes. This inhibition can result in altered receptor signaling pathways, which are crucial in understanding the receptor's physiological roles beyond olfaction, particularly in non-olfactory tissues where such receptors are increasingly being studied.
The development of Olr1642 inhibitors involves the identification of key structural motifs within these molecules that can interact efficiently with the receptor's active site. These inhibitors are often designed using structure-based drug design (SBDD) approaches, where computational models of the receptor are used to screen and optimize potential inhibitory compounds. Key to the effectiveness of these inhibitors is their ability to achieve selectivity, meaning they should interact with the Olr1642 receptor without affecting other closely related olfactory receptors. Achieving such selectivity often requires a deep understanding of the receptor's binding pocket and the molecular interactions that govern ligand recognition and binding. Research into Olr1642 inhibitors continues to evolve, providing valuable insights into receptor-ligand interactions and the broader implications of GPCR modulation in cellular signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor, potentially disrupts protein degradation pathways. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor, potentially interrupts MAPK/ERK signaling pathways. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Bruton's tyrosine kinase inhibitor, potentially affects B-cell receptor signaling. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
MET, VEGFR2, and RET inhibitor, potentially disrupts cell proliferation and angiogenesis. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
EGFR inhibitor, potentially effective against T790M mutation in lung cancer. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Multi-kinase inhibitor, potentially inhibits angiogenesis and oncogenesis. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK1 and JAK2 inhibitor, potentially affects cytokine and growth factor signaling. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Multi-targeted receptor tyrosine kinase inhibitor, potentially inhibits angiogenesis. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Immunomodulatory drug, potentially affects TNF-α production and angiogenesis. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
BCL-2 inhibitor, potentially induces apoptosis in cancer cells. | ||||||